Tuesday, July 17, 2018
 
 
Company News: Page (1) of 1 - 06/19/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Medibio Receives TGA Approval

(June 19, 2018)

SYDNEY, Australia and MINNEAPOLIS, June 19, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company,  announced today it has received confirmation that the Company’s Depression Diagnostic Aide (DDA) and Mental Health Monitoring Platform (MHM) have been included on the register of Australian Therapeutic Goods Administration (ATGA). Medibio’s DDA and MHM technology underpin the Company’s Mental Index application and Logics platform.

The Company’s regulatory validation now includes both the CE (Conformité Européenne) Mark and Therapeutic Good Administration (TGA) under the GMDN product code 58290 - Psychological assessment system application software.

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.
Further Information:  Website: www.medibio.com.au
 
Shareholder and Investor Inquiries:
Stephanie Ottens
Investor Relations Director
Medibio Limited
[email protected]
T: +61 434 405 400
 Media Inquiries:
Josh Purdy
Senior Public Relations Manager
Medibio Limited
[email protected]
T: +1 952-222-0551 ext. 208
M: +1 612-695-0168

Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Personal Care Home Consultant Lynn Marting Helps Families Find the Right Facility for Aging Loved Ones
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution
  • Progressive Care Inc. Announces Month-End Sales Figures Showing Increase in Year-Over-Year Prescriptions Filled in June 2018
  • Mount Sinai Health System and Arena Address AI-Driven Hiring for Healthcare at Leading Industry Conference
  • Connected Health Devices: Global Market Forecast to 2023 - CAGR to Grow at 21.1%, Driven by the Increasing Adoption of IT in Healthcare

    Cancer
  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  • Corporate Whistleblower Center Now Targets Hospice Providers Ripping Off Medicare And Urges Their Employees with Proof a of Wrongdoing to Call About Rewards -- Don't Get Mad, Get Even
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines